A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy

drug protocol number
MO22223
drug sponsor
Roche
drug study
Bevacizumab+ Capecitabine
drug trial site
KAH & OC
drug status
Terminated
drug phase